Table 1 Characteristics of the included studies
Study | Year | Country | Design | Size | Operation | Median Follow-Up (Month) | Mean Age | Statin Use | Cofactors |
|---|---|---|---|---|---|---|---|---|---|
Post | 2011 | USA | Retrospective | 383 | RP | 49 | 60.9 | / | Age, Race, Preoperative PSA, Gleason Score, Tumor Stage, Surgical Margin Status, Smoking, and Other Metabolic Syndrome Components |
Allott | 2014 | USA | Retrospective | 843 | RP | 74.3 | 60.4 | 427 (50.7%) | Age, Race, Pre-Operative PSA, Year of Surgery, BMI, Surgical Center, Statin Use, Pathological Gleason Score, Prostate Weight, Positive Surgical Margins, Extracapsular Extension, and Seminal Vesicle Invasion |
Shiota | 2014 | Japan | Prospective | 283 | Open (27.2%); LRP (14.8%); RALP (58.0%) | 14.8 | 65 (49–78) a | 48 (20.2%) | Age, Pre-Operative PSA, Clinical T Stage, Pathological Stage, Biopsy Gleason Score, Surgical Approach, Surgical Margin, Pathological Gleason Score, Alteration of Gleason Score, Perineural Invasion, Angiolymphatic Invasion, Lymph Node Status |
Jeannette | 2015 | Puerto Rico | Retrospective | 199 | RP | / | 58.82 | 0 | Age, BMI |
Zhang | 2015 | China | Retrospective | 322 | RP + PLD | / | 68 | 14 (4.3%) | Age, BMI, Hypertension, Diabetes, Smoking Status, Statin Usage, Preoperative PSA, Biopsy Gleason Score, Clinical Stage |
Kang | 2015 | China | Retrospective | 663 | RP | 21 | 68 (62–72) a | / | Biopsy Gleason Score, Pathological Gleason Score, Preoperative PSA, Pathological T Stage, Lymph Node Metastasis, Surgical Margin |
Yoshio | 2016 | Japan | Retrospective | 562 | Open (56.2%); RALP (43.8%) | 54 | 65.9 | 69 (12.3%) | Age, Pre-Operative PSA, BMI, Statin Use, Clinical T Stage, Gleason Score, Extracapsular Extension, Seminal Vesicle Invasion, Surgical Margin, Lympho-Vascular Invasion, Perineural Invasion, Lymph Node Metastases |
Bhindi | 2016 | Canada | Prospective | 1939 | Open (76%); LRP (6.1%); RALP (17.9%) | 31 | 61.5 | 611 (31.5%) | Age, Year Of RP, And Statin Use, Disease Parameters (PSA At Surgery, Final Grade, Pathological Stage, Surgical Margin Status), Surgical Approach of RP And Type of Nerve Sparing |
Wettstein | 2017 | Switzerland | Prospective | 371 | RP | 28 | 63 | 61 (16.4%) | Age, PSA, Extra-prostatic disease (> = pT3), High-risk disease (> = Gleason 8), Positive nodal status (pN1), Positive surgical margins, Statin use |
Colicchia | 2017 | USA | Prospective | 3662 | Open (69.4%); RALP (30.4%) | 102 | / | / | Age at Surgery, Total Number of Positive Cores, Max % Of Tumor in The Core, Clinical Stage, And Log 2 Pre-Surgery PSA. |
Lebdai | 2017 | France | Retrospective | 567 | Open (13.6%) LRP (6.2%); RALP (78.1%) | / | 64 (45–79) a | / | BMI, Abdominal Perimeter, Glycemia, High Blood Pressure |
Rantaniemi | 2018 | Finland | Retrospective | 1314 | RP | 134.4 | / | 467 (35.5%) | Age, Preoperative PSA Level, Pathological T Stage and Gleason Score, Use of Antihypertensive and Antidiabetic Medication, Non-Steroidal Anti-Inflammatory Drugs and Allopurinol, and Surgical Marginal Positivity |